Approval · Notice of Compliance 27896 · 2022
CLINIMIX E: Notice of Compliance 27896
Issued April 1, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27896
- Date
- April 1, 2022
- Company
- Baxter CorporationMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To satisfy the Sponsor¿s commitment to split the current CLINIMIX E / CLINIMIX Product Monograph (PM) into five. To update the PM to align with the 2020 Master Template
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CLINIMIX E | Not yet assigned | — |
Medicinal ingredients
- L-ALANINE 1.656 G per 100ML
- DEXTROSE 10 G per 100ML
- GLYCINE 0.824 G per 100ML
- HISTIDINE 0.384 G per 100ML
- L-ARGININE 0.92 G per 100ML
- L-ISOLEUCINE 0.48 G per 100ML
- L-LEUCINE 0.584 G per 100ML
- L-PHENYLALANINE 0.48 G per 100ML
- L-PROLINE 0.544 G per 100ML
- L-THREONINE 0.336 G per 100ML
- L-TRYPTOPHAN 0.144 G per 100ML
- L-VALINE 0.464 G per 100ML
- L-LYSINE HCL 0.464 G per 100ML
- METHIONINE 0.32 G per 100ML
- POTASSIUM PHOSPHATE DIBASIC 0.261 G per 100ML
- SERINE 0.4 G per 100ML
- SODIUM CHLORIDE 0.205 G per 100ML
- L-TYROSINE 0.032 G per 100ML
- MAGNESIUM CHLORIDE HEXAHYDRATE 0.024 G per 100ML
- CALCIUM CHLORIDE DIHYDRATE 0.033 G per 100ML
- DEXTROSE 14 G per 100ML
- L-PHENYLALANINE 0.448 G per 100ML